Richard Cathomas1, Anja Lorch2, Harman M Bruins3, Eva M Compérat4, Nigel C Cowan5, Jason A Efstathiou6, Rainer Fietkau7, Georgios Gakis8, Virginia Hernández9, Estefania Linares Espinós10, Yann Neuzillet11, Maria J Ribal12, Matthieu Rouanne11, George N Thalmann13, Antoine G van der Heijden14, Erik Veskimäe15, J Alfred Witjes14, Matthew I Milowsky16. 1. Division of Oncology/Hematology, Cantonal Hospital Grisons, Chur, Switzerland. Electronic address: richard.cathomas@ksgr.ch. 2. Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland. 3. Department of Urology, Zuyderland Medical Center, Sittard-Geleen-Heerlen, the Netherlands. 4. Department of Pathology, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Hopital Tenon, Paris, France. 5. Department of Radiology, Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust, Portsmouth, UK. 6. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. 7. Department of Radiation Therapy, University of Erlangen, Erlangen, Germany. 8. Department of Urology and Pediatric Urology, University of Würzburg, Würzburg, Germany. 9. Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. 10. Department of Urology, Hospital Universitario La Paz, Madrid, Spain. 11. Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Suresnes, France. 12. Department of Urology, Hospital Clinic, University of Barcelona, Barcelona, Spain. 13. Department of Urology, Inselspital, University Hospital Bern, Bern, Switzerland. 14. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. 15. Department of Urology, Tampere University Hospital, Tampere, Finland. 16. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Abstract
CONTEXT: Treatment of metastatic urothelial carcinoma is currently undergoing a rapid evolution. OBJECTIVE: This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma. EVIDENCE ACQUISITION: A comprehensive scoping exercise covering the topic of metastatic urothelial carcinoma is performed annually by the Guidelines Panel. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates. EVIDENCE SYNTHESIS: Platinum-based chemotherapy is the recommended first-line standard therapy for all patients fit to receive either cisplatin or carboplatin. Patients positive for programmed death ligand 1 (PD-L1) and ineligible for cisplatin may receive immunotherapy (atezolizumab or pembrolizumab). In case of nonprogressive disease on platinum-based chemotherapy, subsequent maintenance immunotherapy (avelumab) is recommended. For patients without maintenance therapy, the recommended second-line regimen is immunotherapy (pembrolizumab). Later-line treatment has undergone recent advances: the antibody-drug conjugate enfortumab vedotin demonstrated improved overall survival and the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib appears active in case of FGFR3 alterations. CONCLUSIONS: This 2021 update of the EAU guideline provides detailed and contemporary information on the treatment of metastatic urothelial carcinoma for incorporation into clinical practice. PATIENT SUMMARY: In recent years, several new treatment options have been introduced for patients with metastatic urothelial cancer (including bladder cancer and cancer of the upper urinary tract and urethra). These include immunotherapy and targeted treatments. This updated guideline informs clinicians and patients about optimal tailoring of treatment of affected patients.
CONTEXT: Treatment of metastatic urothelial carcinoma is currently undergoing a rapid evolution. OBJECTIVE: This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma. EVIDENCE ACQUISITION: A comprehensive scoping exercise covering the topic of metastatic urothelial carcinoma is performed annually by the Guidelines Panel. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates. EVIDENCE SYNTHESIS: Platinum-based chemotherapy is the recommended first-line standard therapy for all patients fit to receive either cisplatin or carboplatin. Patients positive for programmed death ligand 1 (PD-L1) and ineligible for cisplatin may receive immunotherapy (atezolizumab or pembrolizumab). In case of nonprogressive disease on platinum-based chemotherapy, subsequent maintenance immunotherapy (avelumab) is recommended. For patients without maintenance therapy, the recommended second-line regimen is immunotherapy (pembrolizumab). Later-line treatment has undergone recent advances: the antibody-drug conjugate enfortumab vedotin demonstrated improved overall survival and the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib appears active in case of FGFR3 alterations. CONCLUSIONS: This 2021 update of the EAU guideline provides detailed and contemporary information on the treatment of metastatic urothelial carcinoma for incorporation into clinical practice. PATIENT SUMMARY: In recent years, several new treatment options have been introduced for patients with metastatic urothelial cancer (including bladder cancer and cancer of the upper urinary tract and urethra). These include immunotherapy and targeted treatments. This updated guideline informs clinicians and patients about optimal tailoring of treatment of affected patients.
Authors: Hye Won Lee; Mi Ju Kang; Young-Ju Kwon; Sama Abdi Nansa; Eui Hyun Jung; Sung Han Kim; Sang-Jin Lee; Kyung-Chae Jeong; Youngwook Kim; Heesun Cheong; Ho Kyung Seo Journal: Biomedicines Date: 2022-05-18
Authors: Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575
Authors: Pan Li; Chaohu Chen; Jianpeng Li; Li Yang; Yuhan Wang; Zhilong Dong; Jun Mi; Yunxin Zhang; Juan Wang; Hanzhang Wang; Ronald Rodriguez; Junqiang Tian; Zhiping Wang Journal: Front Genet Date: 2022-04-26 Impact factor: 4.772
Authors: Gianluigi Califano; Idir Ouzaid; Paul Laine-Caroff; Arthur Peyrottes; Claudia Collà Ruvolo; Benjamin Pradère; Vincent Elalouf; Vincent Misrai; Jean-François Hermieu; Shahrokh F Shariat; Evanguelos Xylinas Journal: Curr Oncol Date: 2022-01-29 Impact factor: 3.677